Organigram Global (NASDAQ:OGI) Announces Earnings Results, Misses Estimates By $0.04 EPS

Organigram Global (NASDAQ:OGI) released its earnings results on Tuesday. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.04), Zacks reports. Organigram Global had a negative net margin of 9.22% and a negative return on equity of 13.41%.

Here are the key takeaways from Organigram Global’s conference call:

• Record financial performance: Q3 net revenue rose 49% year over year to CAD 105.8 million, while adjusted EBITDA reached a record CAD 13.4 million and adjusted gross margin expanded to 37%. Management expects fiscal 2026 revenue to exceed CAD 350 million, with margins and EBITDA meaningfully above fiscal 2025 levels.
• Sanity Group is scaling as planned: The German business contributed €24.5 million of revenue during OrganiGram’s ownership period, and international sales represented roughly 35% of consolidated revenue. Management expects Sanity’s revenue growth to continue, with operating expenses remaining relatively stable and creating further P&L leverage.
• Canadian product recovery is gaining traction: New vape hardware and higher-potency products helped improve vape share in June, while infused pre-rolls returned to growth. Flower share increased to 12.5% year over year, and beverages and concentrates also posted strong gains as the company reduces its SKU count and focuses on higher-performing products.
• International supply and margin opportunities remain significant: OrganiGram is improving Canadian flower pass rates, adding suppliers, and pursuing EU GMP-compliant remediation pathways to meet tight German demand. EU GMP certification could meaningfully improve margins by reducing reliance on European processing, although no approval timeline was provided.
• Cash flow remains a near-term concern: Free cash flow was negative CAD 3.9 million in Q3, and management expects negative free cash flow for fiscal 2026 because of working-capital investments supporting the larger Sanity-led business. Cash and cash equivalents were CAD 11.7 million at quarter end, although total liquidity including debt facilities was CAD 49.2 million.

Organigram Global Trading Up 11.0%

Shares of NASDAQ:OGI opened at $1.17 on Tuesday. Organigram Global has a 1 year low of $0.85 and a 1 year high of $2.24. The business has a fifty day simple moving average of $0.98 and a 200 day simple moving average of $1.24. The firm has a market cap of $164.24 million, a price-to-earnings ratio of -8.96 and a beta of 1.46.

Wall Street Analysts Forecast Growth

OGI has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Organigram Global in a research note on Tuesday, June 9th. Wall Street Zen downgraded Organigram Global from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Organigram Global currently has a consensus rating of “Hold”.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of OGI. Millennium Management LLC bought a new stake in shares of Organigram Global in the 4th quarter valued at approximately $1,260,000. Two Sigma Investments LP bought a new position in Organigram Global during the third quarter valued at approximately $907,000. Renaissance Technologies LLC lifted its stake in Organigram Global by 43.2% in the fourth quarter. Renaissance Technologies LLC now owns 1,405,348 shares of the company’s stock valued at $2,361,000 after acquiring an additional 423,900 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Organigram Global by 82.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 466,585 shares of the company’s stock valued at $784,000 after acquiring an additional 210,391 shares during the last quarter. Finally, Lazard Asset Management LLC bought a new stake in Organigram Global in the fourth quarter worth approximately $280,000. 34.63% of the stock is owned by institutional investors and hedge funds.

Organigram Global Company Profile

Organigram Global Inc (NASDAQ: OGI) is a licensed producer of cannabis and hemp products headquartered in Moncton, New Brunswick, Canada. Founded in 2013, the company operates a state-of-the-art cultivation and manufacturing facility spanning more than one million square feet. Organigram holds licenses from Health Canada to produce and sell both medical and adult-use cannabis, and it pursues Good Manufacturing Practice (GMP) certification to support international exports.

The company’s product portfolio encompasses dried flower, pre-rolled joints, cannabis oils, capsules and soft gels, as well as vapourizer cartridges and extracts.